The DMC has recommended FIVE times that the LibiGel safety study continue as per FDA-approved protocol, with no modifications, since there are no signals or markers that would indicate that LibiGel is less than safe.
Therefore, the Phase III LibiGel (testosterone gel) safety study will continue as per the FDA-agreed protocol, without modifications including continued enrollment of new subjects.